Huntington Beach Vape Shop
Letter data
- Company
- Huntington Beach Vape Shop
- Recipient
- Jim Petty | Huntington Beach Vape Shop | 365 Pilot Road | Suite B | Las Vegas | , | NV | 89119 | United States | jim.petty@icloud.com | iyad.sabbah77@gmail.com
- Issue date
- 2018-10-24
- Posted date
- Not available
- FDA office
- Center for Tobacco Products
- Subject
- Not available
- Product
- Tobacco
- CMS ID
- 562781
- Reference number
- 1800927
- FEI
- Not available
- Inspection dates
- 2018-09-19 to 2018-10-02
Normalized citations
21 CFR: None found
21 U.S.C.: None found
Related FDA links
No related FDA letter link is present in the source index.
Full source text
CLOSEOUT LETTER
Huntington Beach Vape Shop
MARCS-CMS 562781 —
October 24, 2018
More Warning Letters
Warning Letters
About Warning and Close-Out Letters
Delivery Method:
VIA UPS and Electronic Mail
Reference #:
1800927
Product:
Tobacco
Recipient:
Recipient Name
Jim Petty
Huntington Beach Vape Shop
365 Pilot Road
Suite B
Las Vegas
,
NV
89119
United States
jim.petty@icloud.com
iyad.sabbah77@gmail.com
Issuing Office:
Center for Tobacco Products
10903 New Hampshire Avenue
Silver Spring
,
MD
20993
United States
Dear Jim Petty:
On September 12, 2018, the United States Food and Drug Administration's (FDA) Center for Tobacco Products (CTP) issued you a Warning Letter informing you that your Candy King Batch e-liquid product is misbranded under section 903(a)(1) and/or 903(a)(7)(A) of the Federal Food, Drug, and Cosmetic Act (FD&C Act) because its labeling and/or advertising is false or misleading. Specifically, FDA determined that the labeling and/or advertising of your Candy King Batch e-liquid is misleading under section 903(a)(1) and/or 903(a)(7)(A) of the FD&C Act because it causes the product to imitate food products, particularly ones that are marketed toward, and/or appealing to, children.
On September 19, 2018 and October 2, 2018, you sent FDA a response to the Warning Letter. In response to the Warning Letter, you stated you implemented corrective actions to address the violation identified in the Warning Letter. Based on our evaluation, it appears that you have taken steps to address the violations identified in the Warning Letter.
This letter does not relieve you or your firm from the responsibility of taking all necessary steps to ensure sustained compliance with the FD&C Act and its implementing regulations or with other relevant legal authority. This letter also will not preclude any regulatory action should violations be observed in the future.
Should you have any questions or concerns, please contact me at
(301) 796-9235
or by email at
elenita.ibarrapratt@fda.hhs.gov
.
Sincerely,
/S/
Ele Ibarra-Pratt
Division Director
Office of Compliance and Enforcement
Center for Tobacco Products
VIA UPS and Electronic Mail
cc:
Azim Chowdhury
Keller and Heckman LLP
1001 G Street NW, Suite 500 West
Washington, DC 20001
chowdhury@khlaw.com
GoDaddy, LLC
abuse@godaddy.com
Shopify, Inc.
abuse@shopify.com
Content current as of:
04/11/2019
Regulated Product(s)
Tobacco